全文获取类型
收费全文 | 2159646篇 |
免费 | 154161篇 |
国内免费 | 2838篇 |
专业分类
耳鼻咽喉 | 29527篇 |
儿科学 | 70402篇 |
妇产科学 | 59056篇 |
基础医学 | 314915篇 |
口腔科学 | 60370篇 |
临床医学 | 197381篇 |
内科学 | 414258篇 |
皮肤病学 | 47891篇 |
神经病学 | 169099篇 |
特种医学 | 82241篇 |
外国民族医学 | 461篇 |
外科学 | 315847篇 |
综合类 | 44633篇 |
现状与发展 | 3篇 |
一般理论 | 781篇 |
预防医学 | 167117篇 |
眼科学 | 49345篇 |
药学 | 165379篇 |
11篇 | |
中国医学 | 4524篇 |
肿瘤学 | 123404篇 |
出版年
2018年 | 22623篇 |
2017年 | 17512篇 |
2016年 | 19494篇 |
2015年 | 22162篇 |
2014年 | 30642篇 |
2013年 | 45957篇 |
2012年 | 62708篇 |
2011年 | 66579篇 |
2010年 | 38990篇 |
2009年 | 37138篇 |
2008年 | 62595篇 |
2007年 | 66955篇 |
2006年 | 67232篇 |
2005年 | 64979篇 |
2004年 | 62344篇 |
2003年 | 59924篇 |
2002年 | 57930篇 |
2001年 | 104426篇 |
2000年 | 106845篇 |
1999年 | 89676篇 |
1998年 | 23946篇 |
1997年 | 21468篇 |
1996年 | 21659篇 |
1995年 | 20354篇 |
1994年 | 18845篇 |
1993年 | 17701篇 |
1992年 | 69538篇 |
1991年 | 67590篇 |
1990年 | 66041篇 |
1989年 | 63844篇 |
1988年 | 58462篇 |
1987年 | 57045篇 |
1986年 | 54200篇 |
1985年 | 51054篇 |
1984年 | 38058篇 |
1983年 | 32751篇 |
1982年 | 18787篇 |
1981年 | 16725篇 |
1979年 | 35324篇 |
1978年 | 24970篇 |
1977年 | 21561篇 |
1976年 | 19453篇 |
1975年 | 21441篇 |
1974年 | 25630篇 |
1973年 | 25012篇 |
1972年 | 23822篇 |
1971年 | 22298篇 |
1970年 | 20828篇 |
1969年 | 19870篇 |
1968年 | 18171篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
961.
Can quality of life be quantified? 总被引:1,自引:0,他引:1
E. F. Juniper 《Clinical & Experimental Allergy Reviews》2002,2(2):57-60
962.
963.
964.
B. Tutluolu S. At A. N. Anakkaya E. Altu G. A. Tosun M. Yaman 《Clinical and experimental allergy》2002,32(8):1170-1173
OBJECTIVE: This study aimed to investigate the rate of occupational sensitization to horse hair in grooms and whether occupational exposure to horse hair increases respiratory and allergic symptoms and affects lung function in grooms or not. METHODS: This is a cross-sectional study. Two hundred grooms were randomly selected among 1000 grooms working in Veliefendi Hippodrome of Istanbul. One hundred and twenty-five subjects agreed to enter the study. Ninety-two workers who worked in the different parts of this hippodrome enrolled as the control group. A detailed questionnaire including respiratory and allergic symptoms was filled in, physical examination, skin prick tests and pulmonary function tests were performed. RESULTS: Sensitization to horse hair was 12.8% in grooms and 4.3% in controls. The difference was statistically significant (P = 0.0035). Asthma was found in 14.4% of the grooms and 5.4% of the controls, allergic rhinitis in 42.4% of the grooms and 18.4% of the controls, allergic conjunctivitis in 35.2% of the grooms and 15.2% of the controls, and allergic skin diseases in 32.8% of the grooms and 13% of the controls. The differences were statistically significant (P = 0.043, P = 0.0002, P = 0.001 and P = 0.0008, respectively). The means of FEV1, FEV1/FVC and FVC parameters were significantly lower in the groom group (P = 0.006, P = 0.001 and P = 0.003, respectively). In the multivariate analysis, being in the groom group and working years were found to be predictive factors for impairments of lung function (P < 0.001 and P = 0.002, respectively). CONCLUSION: Occupational exposure to horse increases the sensitization to horse hair, induces asthma and allergic symptoms and also impairs lung functions. 相似文献
965.
A. O. Azghani J. W. Baker S. Shetty E. J. Miller G. J. Bhat 《Inflammation research》2002,51(10):506-510
OBJECTIVE AND DESIGN: Bacterial products as well as the host airway inflammatory responses contribute to the pathogenesis of Pseudomonas infections. We sought to determine if Pseudomonas elastase (PE) induces mitogen-activated protein (MAP) kinase activity in association with interleukin-8 (IL-8) production by alveolar epithelial cells. METHODS: We utilized Western blot analysis to detect phosphorylation of signaling intermediates and ELISA was used to measure IL-8 production. RESULTS: We found that PE induces phosphorylation of the extracellular signal-regulated (ERK1/2) proteins of the MAPK pathway in A549 epithelial cells. Similar results were obtained using primary cultures of rabbit alveolar type II epithelial cells. PE also enhanced IL-8 production, which was abolished in the presence of the ERK activation inhibitor U0126. CONCLUSIONS: We conclude that PE activates the ERK1/2 arm of the MAPK pathway and that activation of this pathway results in enhanced IL-8 production. The results demonstrate that PE may augment pulmonary inflammation via cellular signaling that regulates expression of IL-8. 相似文献
966.
Previously, we prepared two different monoclonal antibodies (mAbs) against human 4-1BB (CD137): an agonistic mAb BBK-1 and an antagonistic mAb BBK-2. In this paper, we describe the molecular cloning of these two mAbs and present comparisons of their amino acid sequences. cDNAs encoding the heavy (H) and light (L) chains of the two mAbs were cloned by screening of cDNA libraries constructed from hybridomas secreting these mAbs. Comparisons of amino acid sequences of the two mAbs showed that, while the constant regions of the H and L chains were identical between the two mAbs, the variable region showed 45% identity in H chains and 48% identity in L chains. This suggests that these two mAbs recognize different epitopes of 4-1BB and may have different effects on the activity of 4-1BB. 相似文献
967.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
968.
Abra R. M. Hunt C. Anthony Fu K. K. Peters J. H. 《Cancer chemotherapy and pharmacology》1983,11(2):98-101
Cancer Chemotherapy and Pharmacology - Addition of solid doxorubicin or solutions to pre-formed liposomes proved to be the optimal method for incorporating the drug into liposomes whilst... 相似文献
969.
We describe a simple direct extraction method for the gas-liquid chromatography determination of serum valproic acid. The working range for the assay is 2-180 mg/L and our within-run precision was 5.8 and 4.3% at the 40 and 90 mg/L concentrations respectively. Hemolyzed and lipemic sera as well as samples from patients with hyperbilirubinemia and from patients with decreased renal function were put through the assay and no interfering peaks were noted. Interference occurred when teflon-lined screw caps were used during the extraction step. The method was proven to be accurate by linear regression analysis of samples containing weighed-in amounts of valproic acid. The above assay was compared to an enzyme immunoassay technique (EMIT). The working range for the latter is 10-150 mg/L and the with-run precision was 10.8 and 5.9% and 90 mg/L concentration respectively. Samples were run by both the gas-liquid chromatograph and enzyme immunoassay methods and gave very similar results over the range 16-139 mg/L. 相似文献